Elanco Animal Health Inc
ELAN22.305USD
+0.215+0.97%
Cierre 12/19, 16:00（ET）Cotizaciones retrasadas 15 min
11.08BCap. mercado
308.38P/E TTM
Más Datos de Elanco Animal Health Inc Compañía
Elanco Animal Health Incorporated is an animal health company delivering products and services to prevent and treat disease in farm animals and pets. The Company's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). It has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The Company's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.
Información de Elanco Animal Health Inc
Símbolo de cotizaciónELAN
Nombre de la empresaElanco Animal Health Inc
Fecha de salida a bolsaSep 20, 2018
Director ejecutivoSimmons (Jeffrey N)
Número de empleados9000
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 20
Dirección450 Elanco Circle
CiudadINDIANAPOLIS
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísUnited States of America
Código postal46221
Teléfono18773526261
Sitio Webhttps://www.elanco.com/
Símbolo de cotizaciónELAN
Fecha de salida a bolsaSep 20, 2018
Director ejecutivoSimmons (Jeffrey N)
Ejecutivos de Elanco Animal Health Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jeffrey N. (Jeff) Simmons
Mr. Jeffrey N. (Jeff) Simmons
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.36M
+36.70%
Mr. David Kinard
Mr. David Kinard
Executive Vice President - Human Resources, Corporate Communications and Administration
Executive Vice President - Human Resources, Corporate Communications and Administration
205.68K
+7.83%
Mr. Lawrence Erik Kurzius
Mr. Lawrence Erik Kurzius
Independent Chairman of the Board
Independent Chairman of the Board
160.34K
+6.87%
Mr. Michael J. Harrington
Mr. Michael J. Harrington
Independent Director
Independent Director
109.58K
+10.39%
Mr. Art A. Garcia, CPA
Mr. Art A. Garcia, CPA
Independent Director
Independent Director
91.28K
+12.74%
Dr. Deborah Turner Kochevar, Ph.D.
Dr. Deborah Turner Kochevar, Ph.D.
Independent Director
Independent Director
89.71K
+12.99%
Mr. Paul S. Herendeen
Mr. Paul S. Herendeen
Independent Director
Independent Director
84.81K
+13.84%
Mr. Timothy J. (Tim) Bettington
Mr. Timothy J. (Tim) Bettington
Executive Vice President - Corporate Strategy and Market Development
Executive Vice President - Corporate Strategy and Market Development
80.40K
-22.66%
Mr. James Meer
Mr. James Meer
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
62.55K
-1.82%
Ms. Shiv O'Neill
Ms. Shiv O'Neill
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
53.92K
+100.82%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Jeffrey N. (Jeff) Simmons
Mr. Jeffrey N. (Jeff) Simmons
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.36M
+36.70%
Mr. David Kinard
Mr. David Kinard
Executive Vice President - Human Resources, Corporate Communications and Administration
Executive Vice President - Human Resources, Corporate Communications and Administration
205.68K
+7.83%
Mr. Lawrence Erik Kurzius
Mr. Lawrence Erik Kurzius
Independent Chairman of the Board
Independent Chairman of the Board
160.34K
+6.87%
Mr. Michael J. Harrington
Mr. Michael J. Harrington
Independent Director
Independent Director
109.58K
+10.39%
Mr. Art A. Garcia, CPA
Mr. Art A. Garcia, CPA
Independent Director
Independent Director
91.28K
+12.74%
Dr. Deborah Turner Kochevar, Ph.D.
Dr. Deborah Turner Kochevar, Ph.D.
Independent Director
Independent Director
89.71K
+12.99%
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Por negocioUSD
Nombre
Ganancia
Proporción
Pet Health
643.00M
51.81%
Farm Animal
583.00M
46.98%
Contract Manufacturing
15.00M
1.21%
Por regiónUSD
Nombre
Ganancia
Proporción
International
648.00M
52.22%
United States
593.00M
47.78%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Pet Health
643.00M
51.81%
Farm Animal
583.00M
46.98%
Contract Manufacturing
15.00M
1.21%
Estadísticas de accionistas
Actualizado: dom., 16 de nov
Actualizado: dom., 16 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Dodge & Cox
16.66%
Fidelity Management & Research Company LLC
10.21%
PRIMECAP Management Company
10.05%
The Vanguard Group, Inc.
9.75%
BlackRock Institutional Trust Company, N.A.
8.13%
Otro
45.19%
Accionistas
Accionistas
Proporción
Dodge & Cox
16.66%
Fidelity Management & Research Company LLC
10.21%
PRIMECAP Management Company
10.05%
The Vanguard Group, Inc.
9.75%
BlackRock Institutional Trust Company, N.A.
8.13%
Otro
45.19%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
70.39%
Investment Advisor/Hedge Fund
36.66%
Hedge Fund
5.79%
Research Firm
1.90%
Individual Investor
1.13%
Pension Fund
1.08%
Bank and Trust
0.65%
Sovereign Wealth Fund
0.18%
Family Office
0.11%
Participación institucional
Actualizado: lun., 8 de dic
Actualizado: lun., 8 de dic
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q4
852
577.24M
120.43%
+30.91K
2025Q3
891
577.57M
121.95%
+32.95M
2025Q2
878
543.55M
113.98%
+36.20M
2025Q1
945
503.90M
116.31%
-73.53M
2024Q4
964
498.16M
117.36%
+7.74M
2024Q3
970
490.73M
118.81%
+19.54K
2024Q2
1004
491.01M
118.24%
+1.27M
2024Q1
1021
489.85M
119.72%
-100.34M
2023Q4
1018
489.74M
120.73%
-3.72M
2023Q3
1027
490.57M
119.00%
+3.49M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Dodge & Cox
82.90M
16.69%
-25.35K
-0.03%
Jun 30, 2025
Fidelity Management & Research Company LLC
48.24M
9.71%
+9.93M
+25.93%
Jun 30, 2025
PRIMECAP Management Company
51.77M
10.42%
+1.54M
+3.07%
Jun 30, 2025
The Vanguard Group, Inc.
47.65M
9.59%
-496.16K
-1.03%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
19.58M
3.94%
-484.75K
-2.42%
Jun 30, 2025
T. Rowe Price Investment Management, Inc.
19.55M
3.94%
+3.57M
+22.35%
Jun 30, 2025
Dimensional Fund Advisors, L.P.
22.75M
4.58%
+2.28M
+11.15%
Jun 30, 2025
UBS Financial Services, Inc.
10.31M
2.08%
+5.99M
+138.56%
Jun 30, 2025
State Street Investment Management (US)
9.13M
1.84%
-125.36K
-1.35%
Jun 30, 2025
Fidelity Institutional Asset Management
16.64M
3.35%
+1.09M
+7.01%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
iShares U.S. Pharmaceuticals ETF
4.06%
Adaptiv Select ETF
3.38%
State Street SPDR S&P Pharmaceuticals ETF
3.15%
Brandes US Small-Mid Cap Value ETF
3.14%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.84%
VanEck Agribusiness ETF
2.3%
First Trust Health Care Alphadex Fund
1.92%
Federated Hermes MDT Large Cap Value ETF
1.9%
First Trust NASDAQ Pharmaceuticals ETF
1.33%
Invesco S&P MidCap 400 Pure Value ETF
1.22%
Ver más
iShares U.S. Pharmaceuticals ETF
Proporción4.06%
Adaptiv Select ETF
Proporción3.38%
State Street SPDR S&P Pharmaceuticals ETF
Proporción3.15%
Brandes US Small-Mid Cap Value ETF
Proporción3.14%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción2.84%
VanEck Agribusiness ETF
Proporción2.3%
First Trust Health Care Alphadex Fund
Proporción1.92%
Federated Hermes MDT Large Cap Value ETF
Proporción1.9%
First Trust NASDAQ Pharmaceuticals ETF
Proporción1.33%
Invesco S&P MidCap 400 Pure Value ETF
Proporción1.22%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Elanco Animal Health Inc?
Los cinco principales accionistas de Elanco Animal Health Inc son:
Dodge & Cox posee 82.90M acciones, lo que representa el 16.69% del total de acciones.
Fidelity Management & Research Company LLC posee 48.24M acciones, lo que representa el 9.71% del total de acciones.
PRIMECAP Management Company posee 51.77M acciones, lo que representa el 10.42% del total de acciones.
The Vanguard Group, Inc. posee 47.65M acciones, lo que representa el 9.59% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 19.58M acciones, lo que representa el 3.94% del total de acciones.
Dodge & Cox posee 82.90M acciones, lo que representa el 16.69% del total de acciones.
Fidelity Management & Research Company LLC posee 48.24M acciones, lo que representa el 9.71% del total de acciones.
PRIMECAP Management Company posee 51.77M acciones, lo que representa el 10.42% del total de acciones.
The Vanguard Group, Inc. posee 47.65M acciones, lo que representa el 9.59% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 19.58M acciones, lo que representa el 3.94% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Elanco Animal Health Inc?
Los tres principales tipos de accionista de Elanco Animal Health Inc son:
Dodge & Cox
Fidelity Management & Research Company LLC
PRIMECAP Management Company
Dodge & Cox
Fidelity Management & Research Company LLC
PRIMECAP Management Company
¿Cuántas instituciones poseen acciones de Elanco Animal Health Inc (ELAN)?
A fecha de 2025Q4, 852 instituciones poseen acciones de Elanco Animal Health Inc, con un valor de mercado combinado de aproximadamente 577.24M, lo que representa el 120.43% del total de acciones. En comparación con el 2025Q3, el accionariado institucional ha aumentado en -1.52%.
¿Cuál es la mayor fuente de ganancias de Elanco Animal Health Inc?
El FY2025Q2, el segmento empresarial Pet Health generó la ganancia más alta para Elanco Animal Health Inc, ascendiendo a 643.00M y representando el 51.81% de la ganancia total.
